Bone target radiotracers for palliative therapy of bone metastases

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3290-3300

  Ogawa, K ^a   Washiyama, K ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bone metastases; Bone seeking radiopharmaceuticals; Pain; Palliation

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID BIS 212; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID PB; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID TH 227; BISMUTH 212; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; LEAD; LEXIDRONAM SAMARIUM SM 153; LEXIDRONAM TH 227; PHOSPHONIC ACID DERIVATIVE; PHOSPHORUS 32; RADIUM; RADIUM 223 CHLORIDE; RHENIUM 186; RHENIUM 188; RHENIUM COMPLEX; STRONTIUM 89; SUCCIMER; SUCCIMER RE 186; SUCCIMER RE 188; TETRAXETAN; TETRAXETAN Y 90; THORIUM DERIVATIVE; TRACER; UNCLASSIFIED DRUG; YTTRIUM 90;

BONE METASTASIS; CANCER PALLIATIVE THERAPY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; NONHUMAN; REVIEW;

ALPHA PARTICLES; ANIMALS; BONE AND BONES; BONE NEOPLASMS; HUMANS; PALLIATIVE CARE; RADIOACTIVE TRACERS;

EID: 84863732146     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215865     Document Type: Review

References (121)

1. Yoneda, T.; Sasaki, A.; Mundy, G.R., Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat, 1994, 32, (1), 73-84.
2. Coleman, R.E., Skeletal complications of malignancy. Cancer, 1997, 80, (8 Suppl), 1588-1594.
3. Portenoy, R.K.; Lesage, P., Management of cancer pain. Lancet, 1999, 353, (9165), 1695-1700.
4. Portenoy, R.K.; Payne, D.; Jacobsen, P., Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999, 81, (1-2), 129-134.
5. Mercadante, S., Malignant bone pain: pathophysiology and treatment. Pain, 1997, 69, (1-2), 1-18.
6. Clines, G.A.; Guise, T.A., Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med, 2008, 10, e7.
7. Bonica, J.J., Importance of effective pain control. Acta Anaesthesiol Scand Suppl, 1987, 85, 1-16.
8. Arcangeli, G.; Giovinazzo, G.; Saracino, B.; D'Angelo, L.; Giannarelli, D.; Micheli, A., Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys, 1998, 42, (5), 1119-1126.
9. Lewington, V.J., Bone-seeking radionuclides for therapy. J Nucl Med, 2005, 46 Suppl 1, 38S-47S.
10. Friedell, H.L.; Storaasli, J.P., The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther, 1950, 64, (4), 559-575.
11. Marshak, A., Uptake of Radioactive Phosphorus by Nuclei of Liver and Tumors. Science, 1940, 92, (2394), 460-461.
12. 32P therapy and sequential hemibody irradiation (HBI) for bony metastases as methods of whole body irradiation. Am J Clin Oncol, 1986, 9, (3), 264-268.
13. 2 incorporation into type I collagen during bone mineralization. J Nucl Med, 2000, 41, (1), 183-188.
14. Blake, G.M.; Zivanovic, M.A.; McEwan, A.J.; Ackery, D.M., Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med, 1986, 12, (9), 447-454.
15. Silberstein, E.B.; Williams, C., Strontium-89 therapy for the pain of osseous metastases. J Nucl Med, 1985, 26, (4), 345-348.
16. Paes, F.M.; Serafini, A.N., Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med, 2010, 40, (2), 89-104.
17. Paes, F.M.; Ernani, V.; Hosein, P.; Serafini, A.N., Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol, 2011, 9, (6), 197-205.
18. Liepe, K.; Kotzerke, J., Internal radiotherapy of painful bone metastases. Methods, 2011, 55, (3), 258-270.
19. Laing, A.H.; Ackery, D.M.; Bayly, R.J.; Buchanan, R.B.; Lewington, V.J.; McEwan, A.J.; Macleod, P.M.; Zivanovic, M.A., Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol, 1991, 64, (765), 816-822.
20. Porter, A.T.; McEwan, A.J.; Powe, J.E.; Reid, R.; McGowan, D.G.; Lukka, H.; Sathyanarayana, J.R.; Yakemchuk, V.N.; Thomas, G.M.; Erlich, L.E.; et al., Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys, 1993, 25, (5), 805-813.
21. Tu, S.M.; Millikan, R.E.; Mengistu, B.; Delpassand, E.S.; Amato, R.J.; Pagliaro, L.C.; Daliani, D.; Papandreou, C.N.; Smith, T.L.; Kim, J.; Podoloff, D.A.; Logothetis, C.J., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet, 2001, 357, (9253), 336-341.
22. 153Sm radiotherapeutic bone agents. Int J Rad Appl Instrum B, 1986, 13, (4), 479-482.
23. Tse, J.W.; Wiebe, L.I.; Noujaim, A.A., High specific activity [samarium-153] EDTA for imaging of experimental tumor models. J Nucl Med, 1989, 30, (2), 202-208.
24. Eary, J.F.; Collins, C.; Stabin, M.; Vernon, C.; Petersdorf, S.; Baker, M.; Hartnett, S.; Ferency, S.; Addison, S.J.; Appelbaum, F.; et al., Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med, 1993, 34, (7), 1031-1036.
25. 153Sm-EDTMP. Eur J Nucl Med Mol Imaging, 2009, 36, (1), 122-129.
26. Singh, A.; Holmes, R.A.; Farhangi, M.; Volkert, W.A.; Williams, A.; Stringham, L.M.; Ketring, A.R., Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med, 1989, 30, (11), 1814-1818.
27. Bayouth, J.E.; Macey, D.J.; Kasi, L.P.; Fossella, F.V., Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med, 1994, 35, (1), 63-69.
28. Collins, C.; Eary, J.F.; Donaldson, G.; Vernon, C.; Bush, N.E.; Petersdorf, S.; Livingston, R.B.; Gordon, E.E.; Chapman, C.R.; Appelbaum, F.R., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med, 1993, 34, (11), 1839-1844.
29. Dickie, G.J.; Macfarlane, D., Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol, 1999, 43, (4), 476-479.
30. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging, 2008, 35, (4), 756-765.
31. Larsen, M.; Willett, R.; Yount, R.G., Imidodiphosphate and pyrophosphate: possible biological significance of similar structures. Science, 1969, 166, (3912), 1510-1511.
32. Meyer, J.L.; Nancollas, G.H., The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res, 1973, 13, (4), 295-303.
33. Galasko, C.S., Mechanism of uptake of bone imaging isotopes by skeletal metastases. Clin Nucl Med, 1980, 5, (12), 565-568.
34. 4)-MDP radiopharmaceutical analogues. Int J Appl Radiat Isot, 1983, 34, (12), 1577-1584.
35. Wilson, G.M.; Pinkerton, T.C., Determination of charge and size of technetium diphosphonate complexes by anion-exchange liquid chromatography. Anal Chem, 1985, 57, 246-253.
36. 186ReHEDP. Inorg Chem, 1997, 36, (14), 3055-3063.
37. de Klerk, J.M.; van Dijk, A.; van het Schip, A.D.; Zonnenberg, B.A.; van Rijk, P.P., Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med, 1992, 33, (5), 646-651.
38. de Klerk, J.M.; van het Schip, A.D.; Zonnenberg, B.A.; van Dijk, A.; Stokkel, M.P.; Han, S.H.; Blijham, G.H.; van Rijk, P.P., Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med, 1994, 35, (9), 1423-1428.
39. de Klerk, J.M.; Zonnenberg, B.A.; van het Schip, A.D.; van Dijk, A.; Han, S.H.; Quirijnen, J.M.; Blijham, G.H.; van Rijk, P.P., Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med, 1994, 21, (10), 1114-1120.
40. Bodei, L.; Lam, M.; Chiesa, C.; Flux, G.; Brans, B.; Chiti, A.; Giammarile, F., EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging, 2008, 35, (10), 1934-1940.
41. Maxon, H.R., 3rd; Schroder, L.E.; Hertzberg, V.S.; Thomas, S.R.; Englaro, E.E.; Samaratunga, R.; Smith, H.; Moulton, J.S.; Williams, C.C.; Ehrhardt, G.J.; et al., Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med, 1991, 32, (10), 1877-1881.
42. Maxon, H.R., 3rd; Thomas, S.R.; Hertzberg, V.S.; Schroder, L.E.; Englaro, E.E.; Samaratunga, R.; Scher, H.I.; Moulton, J.S.; Deutsch, E.A.; Deutsch, K.F.; et al., Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med, 1992, 22, (1), 33-40.
43. Dafermou, A.; Colamussi, P.; Giganti, M.; Cittanti, C.; Bestagno, M.; Piffanelli, A., A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med, 2001, 28, (7), 788-798.
44. O'Sullivan, J.M.; McCready, V.R.; Flux, G.; Norman, A.R.; Buffa, F.M.; Chittenden, S.; Guy, M.; Pomeroy, K.; Cook, G.; Gadd, J.; Treleaven, J.; Al-Deen, A.; Horwich, A.; Huddart, R.A.; Dearnaley, D.P., High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer, 2002, 86, (11), 1715-1720.
45. 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging, 2006, 33, (9), 1055-1061.
46. 186Rhenium- HEDP in patients with lung cancer. Q J Nucl Med Mol Imaging, 2004, 48, (3), 211-219.
47. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging, 2004, 31 Suppl 1, S162-170.
48. Limouris, G.; Shukla, S.K.; Manetou, A.; Kouvaris, I.; Plataniotis, G.; Triantafyllou, N.; Rigas, A.V.; Vlahos, L., Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Anticancer Res, 1997, 17, (3B), 1699-1704.
49. Palmedo, H.; Bender, H.; Dierke-Dzierzon, C.; Carl, U.M.; Risse, J.; Krebs, D.; Biersack, H.J., Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med, 1999, 24, (9), 643-648.
50. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases. Q J Nucl Med, 2001, 45, (1), 84-90.
51. 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med, 2011, 52, (11), 1721-1726.
52. Knapp, F.F., Jr.; Beets, A.L.; Guhlke, S.; Zamora, P.O.; Bender, H.; Palmedo, H.; Biersack, H.J., Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res, 1997, 17, (3B), 1783-1795.
53. 188Re generator. J Nucl Med, 2000, 41, (7), 1271-1278.
54. Jeong, J.M.; Knapp, F.F., Jr., Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med, 2008, 38, (2), S19-29.
55. 99mTc-EHDP: a potential radiopharmaceutical for skeletal imaging. J Nucl Med, 1972, 13, (12), 947-950.
56. Yano, Y.; McRae, J.; Van Dyke, D.C.; Anger, H.O., Technetium-99m-labeled stannous ethane-1-hydroxy-1 1-diphosphonate: a new bone scanning agent. J Nucl Med, 1973, 14, (2), 73-78.
57. Subramanian, G.; McAfee, J.G.; Blair, R.J.; Kallfelz, F.A.; Thomas, F.D., Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med, 1975, 16, (8), 744-755.
58. Bevan, J.A.; Tofe, A.J.; Benedict, J.J.; Francis, M.D.; Barnett, B.L., Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals. J Nucl Med, 1980, 21, (10), 961-966.
59. Hsieh, B.T.; Hsieh, J.F.; Tsai, S.C.; Lin, W.Y.; Wang, S.J.; Ting, G., Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. Nucl Med Biol, 1999, 26, (8), 973-976.
60. Palmedo, H.; Guhlke, S.; Bender, H.; Sartor, J.; Schoeneich, G.; Risse, J.; Grunwald, F.; Knapp, F.F., Jr.; Biersack, H.J., Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med, 2000, 27, (2), 123-130.
61. Liepe, K.; Hliscs, R.; Kropp, J.; Gruning, T.; Runge, R.; Koch, R.; Knapp, F.F., Jr.; Franke, W.G., Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radiopharm, 2000, 15, (3), 261-265.
62. Liepe, K.; Franke, W.G.; Kropp, J.; Koch, R.; Runge, R.; Hliscs, R., [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. Nuklearmedizin, 2000, 39, (6), 146-151.
63. Palmedo, H.; Manka-Waluch, A.; Albers, P.; Schmidt-Wolf, I.G.; Reinhardt, M.; Ezziddin, S.; Joe, A.; Roedel, R.; Fimmers, R.; Knapp, F.F., Jr.; Guhlke, S.; Biersack, H.J., Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol, 2003, 21, (15), 2869-2875.
64. Deutsch, E.; Libson, K.; Vanderheyden, J.L.; Ketring, A.R.; Maxon, H.R., The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol, 1986, 13, (4), 465-477.
65. 186Re Complex of 1-Hydroxyethylidene-1, 1-diphosphonate for Treatment of Painful Osseous Metastases. Radioisotopes, 1995, 44, (8), 514-522.
66. Limouris, G.S.; Skukla, S.K., Gastric uptake during Re-186 HEDP bone scintigraphy. Anticancer Res, 1997, 17, (3B), 1779-1781.
67. De Winter, F.; Brans, B.; Van De Wiele, C.; Dierckx, R.A., Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med, 1999, 24, (11), 898-899.
68. 188Re-perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis. Nucl Med Biol, 2000, 27, (1), 83-87.
69. Rogers, M.J.; Watts, D.J.; Russell, R.G., Overview of bisphosphonates. Cancer, 1997, 80, (8 Suppl), 1652-1660.
70. O'Neil, J.P.; Carlson, K.E.; Anderson, C.J.; Welch, M.J.; Katzenellenbogen, J.A., Progestin radiopharmaceuticals labeled with technetium and rhenium: synthesis, binding affinity, and in vivo distribution of a new progestin N2S2-metal conjugate. Bioconjug Chem, 1994, 5, (3), 182-193.
71. Hoepping, A.; Babich, J.; Zubieta, J.A.; Johnson, K.M.; Machill, S.; Kozikowski, A.P., Synthesis and biological evaluation of two novel DATbinding technetium complexes containing a piperidine based analogue of cocaine. Bioorg Med Chem Lett, 1999, 9, (22), 3211-3216.
72. Visser, G.W.; Gerretsen, M.; Herscheid, J.D.; Snow, G.B.; van Dongen, G., Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med, 1993, 34, (11), 1953-1963.
73. van Gog, F.B.; Visser, G.W.; Klok, R.; van der Schors, R.; Snow, G.B.; van Dongen, G.A., Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med, 1996, 37, (2), 352-362.
74. Ogawa, K.; Mukai, T.; Arano, Y.; Hanaoka, H.; Hashimoto, K.; Nishimura, H.; Saji, H., Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Cmp Radiopharm, 2004, 47, (10), 753-761.
75. Ogawa, K.; Mukai, T.; Arano, Y.; Ono, M.; Hanaoka, H.; Ishino, S.; Hashimoto, K.; Nishimura, H.; Saji, H., Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem, 2005, 16, (4), 751-757.
76. Ogawa, K.; Mukai, T.; Arano, Y.; Otaka, A.; Ueda, M.; Uehara, T.; Magata, Y.; Hashimoto, K.; Saji, H., Rhenium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol, 2006, 33, (4), 513-520.
77. 186Re- complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med, 2007, 48, (1), 122-127.
78. 186Re-MAG3-HBP), an agent for treatment of painful bone metastases. Eur J Nucl Med Mol Imaging, 2009, 36, (1), 115-121.
79. Ogawa, K.; Mukai, T., Targeted imaging and therapy for bone metastases: control of pharmacokinetics of bone-targeted radiopharmaceuticals. J Drug Del Sci Tech, 2009, 19, (3), 171-176.
80. van Beek, E.; Hoekstra, M.; van de Ruit, M.; Lowik, C.; Papapoulos, S., Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res, 1994, 9, (12), 1875-1882.
81. 6 conjugation. J Bone Miner Res, 2000, 15, (5), 936-943.
82. Fujisawa, R.; Kuboki, Y., Preferential adsorption of dentin and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta, 1991, 1075, (1), 56-60.
83. Medhurst, S.J.; Walker, K.; Bowes, M.; Kidd, B.L.; Glatt, M.; Muller, M.; Hattenberger, M.; Vaxelaire, J.; O'Reilly, T.; Wotherspoon, G.; Winter, J.; Green, J.; Urban, L., A rat model of bone cancer pain. Pain, 2002, 96, (1-2), 129-140.
84. Kim, S.H.; Chung, J.M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 1992, 50, (3), 355-363.
85. Okada, M.; Nakagawa, T.; Minami, M.; Satoh, M., Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J Pharmacol Exp Ther, 2002, 303, (1), 66-73.
86. 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl Med Biol, 2007, 34, (1), 79-87.
87. 3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem, 2010, 21, (5), 811-815.
88. Kutzner, J.; Hahn, K.; Grimm, W.; Rosler, H.P.; Eckmann, A.; Bender, S., Yttrium-Citrate for pain-therapy by bone metastases [YTTRIUM-90-CITRAT ZUR SCHMERZTHERAPIE BEI KNOCHENMETASTASEN]. NUC Compact, 1990, 21, (4), 128-132.
89. Rosch, F.; Herzog, H.; Plag, C.; Neumaier, B.; Braun, U.; Muller-Gartner, H.W.; Stocklin, G., Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med, 1996, 23, (8), 958-966.
90. 90Y]DOTA- conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol, 2009, 36, (2), 129-135.
91. Ohta, H.; Yamamoto, K.; Endo, K.; Mori, T.; Hamanaka, D.; Shimazu, A.; Ikekubo, K.; Makimoto, K.; Iida, Y.; Konishi, J.; et al., A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med, 1984, 25, (3), 323-325.
92. 99mTc(V)-dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma. World J Surg, 1986, 10, (4), 640-645.
93. Ohta, H.; Endo, K.; Fujita, T.; Nakashima, T.; Sakahara, H.; Torizuka, K.; Shimizu, Y.; Ishii, Y.; Makimoto, K.; Hata, N.; et al., Imaging of head and neck tumors with technetium(V)-99m DMSA. A new tumor-seeking agent. Clin Nucl Med, 1985, 10, (12), 855-860.
94. Kobayashi, H.; Sakahara, H.; Hosono, M.; Shirato, M.; Endo, K.; Kotoura, Y.; Yamamuro, T.; Konishi, J., Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy. Radiology, 1994, 190, (1), 277-280.
95. Hirano, T.; Otake, H.; Shibasaki, T.; Tamura, M.; Endo, K., Differentiating histologic malignancy of primary brain tumors: pentavalent technetium-99m-DMSA. J Nucl Med, 1997, 38, (1), 20-26.
96. Blower, P.J.; Singh, J.; Clarke, S.E., The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid. J Nucl Med, 1991, 32, (5), 845-849.
97. 99mTc-dimercaptosuccinate complex as a tumor imaging agent. Int J Nucl Med Biol, 1985, 12, (4), 273-279.
98. m-DMSA imaging in patients with bone metastases. Nucl Med Commun, 1997, 18, (10), 907-914.
99. Kashyap, R.; Babbar, A.; Sahai, I.; Prakash, R.; Soni, N.L.; Chauhan, U.P., Tc-99m(V) DMSA imaging. A new approach to studying metastases from breast carcinoma. Clin Nucl Med, 1992, 17, (2), 119-122.
100. Hirano, T.; Otake, H.; Yoshida, I.; Endo, K., Primary lung cancer SPECT imaging with pentavalent technetium-99m-DMSA. J Nucl Med, 1995, 36, (2), 202-207.
101. m-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions. Nucl Med Commun, 2000, 21, (3), 251-258.
102. Lam, A.S.; Puncher, M.R.; Blower, P.J., In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid. Eur J Nucl Med, 1996, 23, (12), 1575-1582.
103. Horiuchi-Suzuki, K.; Konno, A.; Ueda, M.; Fukuda, Y.; Nishio, S.; Hashimoto, K.; Saji, H., Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent. Eur J Nucl Med Mol Imaging, 2004, 31, (3), 388-398.
104. 188Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry. Appl Radiat Isot, 2001, 54, (3), 413-418.
105. Blower, P.J.; Lam, A.S.; O'Doherty, M.J.; Kettle, A.G.; Coakley, A.J.; Knapp, F.F., Jr., Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies. Eur J Nucl Med, 1998, 25, (6), 613-621.
106. Hall, E.J.; Giaccia, A.J. Radiobiology for the radiologist. 6th ed. Lippincott Williams & Wilkins: Philadelphia, 2006.
107. Bruland, Ø.S.; Jonasdottir, T.J.; Fisher, D.R.; Larsen, R.H., Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy. Curr Radiopharm, 2008, 1, (3), 203-208.
108. 89Sr in mice. J Nucl Med, 2003, 44, (2), 252-259.
109. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res, 2002, 62, (11), 3120-3125.
110. Larsen, R.H.; Saxtorph, H.; Skydsgaard, M.; Borrebaek, J.; Jonasdottir, T.J.; Bruland, Ø.S.; Klastrup, S.; Harling, R.; Ramdahl, T., Radiotoxicity of the alpha-emitting bone-seeker Ra-223 injected intravenously into mice: Histology, clinical chemistry and hematology. In Vivo, 2006, 20, (3), 325-331.
111. Nilsson, S.; Larsen, R.H.; Fossa, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.E.; Salberg, G.; Bruland, Ø.S., First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res, 2005, 11, (12), 4451-4459.
112. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res, 2006, 12, (20 Pt 2), 6250s-6257s.
113. Nilsson, S.; Franzen, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernas, B.; Petersson, U.; Johannessen, D.C.; Sokal, M.; Pigott, K.; Yachnin, J.; Garkavij, M.; Strang, P.; Harmenberg, J.; Bolstad, B.; Bruland, Ø.S., Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007, 8, (7), 587-594.
114. 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Invest Dr, 2009, 10, (12), 1346-1358.
115. 223Ra in Targeted Alpha-Particle Radiotherapy. Curr Radiopharm, 2011, 4, (4), 283-294.
116. Nilsson, S.; Strang, P.; Aksnes, A.K.; Franzèn, L.; Olivier, P.; Pecking, A.; Staffurth, J.; Vasanthan, S.; Andersson, C.; Bruland, Ø.S. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012, 48, (5), 678-686.
117. Parker, C.; Heinrich, D.; O'Sullivan, J.M.; Fossa, S.; Chodacki, A.; Demkow, T.; Cross, A.; Bolstad, B.; Garcia-Vargas, J.; Sartor, O., Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). Eur J Cancer, 2011, 47 (Suppl. 2), 3.
118. 227Th-EDTMP: a potential therapeutic agent for bone metastasis. Nucl Med Biol, 2004, 31, (7), 901-908.
119. Henriksen, G.; Bruland, Ø.S.; Larsen, R.H., Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res, 2004, 24, (1), 101-105.
120. 212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy. Nucl Med Biol, 1997, 24, (3), 231-237.
121. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev, 2001, 101, (7), 2019-2036.